Skip to Content

Labopharm Gets FDA Approval for Once-a-Day Oleptro

From Associated Press (February 3, 2010)

NEW YORK--Labopharm Inc. said Wednesday it received marketing approval for its antidepressant Oleptro, a once-per-day version of a depression drug that is usually given twice a day.

The Canadian drugmaker said Oleptro was approved to treat major depressive disorder in adults. The drug is a version of the antidepressant trazodone. Labopharm said it is exploring options to bring Oleptro to the U.S. market. It may license the drug to another company or collaborate on sales.

Labopharm said it expects to complete its plans soon, and believes it will launch Oleptro in the U.S. later this year.

Shares of the Laval, Quebec, company surged on the news, rising 49 cents, or 19 percent, to $3.10. The stock finished at $2.61 on Tuesday.


Posted: February 2010